|1.||Szabó, Csaba: 69 articles (11/2015 - 01/2002)|
|2.||Cuzzocrea, Salvatore: 26 articles (09/2015 - 01/2002)|
|3.||Pacher, Pál: 23 articles (01/2015 - 01/2002)|
|4.||Mazzon, Emanuela: 20 articles (09/2015 - 01/2002)|
|5.||Obrosova, Irina G: 20 articles (10/2011 - 08/2003)|
|6.||Liaudet, Lucas: 17 articles (01/2015 - 01/2002)|
|7.||Zhang, Jie: 15 articles (03/2013 - 03/2002)|
|8.||Mabley, Jon G: 14 articles (08/2009 - 03/2002)|
|9.||Szabó, Gábor: 13 articles (10/2007 - 01/2002)|
|10.||Graziani, Grazia: 12 articles (03/2015 - 03/2002)|
10/01/2005 - "Recent progress in the field of DNA repair has demonstrated that transient inhibition of DNA damage detection or repair using potent poly(ADP-ribose) polymerase (PARP) inhibitors could improve the efficacy of cancer treatments. "
09/15/2010 - "More recent data have shown that targeting DNA repair pathways can be effective in selected tumors via a synthetically lethal route, with single agent activity having been shown with poly-ADP ribose polymerase (PARP) inhibitors. "
09/01/2010 - "Drugs that inhibit the enzyme poly(ADP-ribose)polymerase (PARP) are showing considerable promise for the treatment of cancers that have mutations in the BRCA1 or BRCA2 tumor suppressors. "
12/01/2006 - "Inhibitors of poly(ADP-ribose)polymerase (PARP), a nuclear enzyme involved in regulating cell death and cellular responses to DNA repair, show considerable promise in the treatment of cancer both in monotherapy as well as in combination with chemotherapeutic agents and radiation. "
07/01/2014 - "Poly-ADP ribose polymerase (PARP) inhibitors are effective for the treatment of BRCA-deficient tumors. "
|2.||Breast Neoplasms (Breast Cancer)
12/01/2011 - "Poly(ADP-ribose)polymerase (PARP) inhibitors are showing considerable promise for the treatment of BRCA mutation-associated ovarian and breast cancer. "
07/01/2012 - "Promisingly, a number of novel therapeutic agents including antibody-drug conjugates, irreversible small molecule HER2-tyrosine inhibitors, and HER2 dimerization inhibitors show promise in the treatment of HER2-overexpressing MBC, as well as PARP-1 [poly(ADP-ribose) polymerase-1] inhibitors for triple-negative breast cancer."
10/01/2014 - "Poly (ADP-ribose) polymerase (PARP) inhibitors have shown promising results in Breast Cancer (BRCA) deficient breast cancer, but not in molecularly unselected patient populations. "
01/01/2011 - "Inhibitors of poly(ADP-ribose) polymerase (PARP)-mediated DNA repair have shown promise in early clinical studies in the treatment of specific subgroups of breast cancer. "
11/01/2011 - "The development of poly-(ADP)ribose polymerase inhibitors for BRCA1-mutation carriers with TNBC has led the ongoing efforts to translate fundamental biological insights into improved therapies for a difficult-to-treat breast cancer subgroup."
|3.||Ovarian Neoplasms (Ovarian Cancer)
01/11/2011 - "Inhibition of the DNA repair enzyme poly(ADP-ribose) polymerase 1 (PARP1) with small molecules has been shown to be an effective treatment for ovarian cancer with BRCA mutations. "
05/10/2015 - "Based on a series of basic, preclinical and clinical studies, the Poly (ADP-ribose) Polymerase 1 (PARP1) inhibitor, olaparib, has recently been approved for use in ovarian cancer patients with BRCA1 or BRCA2 mutations. "
01/01/2015 - "Poly (ADP-ribose) polymerase 1 (PARP1) inhibitors are actively under clinical trials for the treatment of breast and ovarian cancers that arise due to mutations in BRCA1 and BRCA2. "
07/24/2010 - "Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial."
12/15/2015 - "Interest is also increasing in expanding testing for somatic mutations in ovarian cancer, particularly for genes such as BRCA1 and BRCA2, whereby mutations may allow more patients to benefit from targeted agents, including poly(ADP-ribose) polymerase inhibitors. "
01/01/2014 - "The inhibition of PARP [Poly(ADP-Ribose)Polymerase] by 3-AB showed protective effects against distant liver injury triggered by renal ischemia-reperfusion by the ameliorating effects of 3-AB on oxidative stress."
04/01/2013 - "PRX2 ameliorated poly(ADP-ribose) polymerase 1, p53, Bax, and caspase activation after ischemia. "
02/01/2013 - "To investigate the effect of poly (ADP-ribose) polymerase (PARP) in heart ischemia and reperfusion (I/R) injury in rat and on Akt mediated signaling pathway. "
01/01/2013 - "Therefore, we investigated if inhibition of poly(ADP-ribose) polymerase (PARP) in the therapeutically added cells would lead to their increased viability and, subsequently, to an enhanced effect in an in vitro simulated ischemia-reperfusion (I-R) setting. "
12/01/2012 - "To investigate the effect of Poly (ADP-ribose) polymerase (PARP) inhibition on ischemia/reperfusion (I/R) induced myocardial injury in rat and related mechanisms. "
01/01/2013 - "The protective effects of DPQ were associated with the suppression of inflammation and the activation of the Akt signalling pathways suggesting that the inhibition of poly (ADP-ribose) polymerase reduced heart I/R injury in rats."
11/01/2010 - "In previous studies it has been shown that poly(ADP-ribose) polymerase (PARP) inhibition reduces the extent of inflammation in CHS. "
06/01/2015 - "Nuclear enzyme poly(ADP-ribose) polymerase 1 (PARP-1) is associated with inflammation response. "
06/01/2015 - "Poly(ADP-ribose) polymerase 1 inhibition prevents interleukin-1β-induced inflammation in human osteoarthritic chondrocytes."
07/01/2014 - "Oxidative stress activates poly(ADP-ribose)-polymerase (PARP-1), which promotes inflammation and cell death. "
|2.||Proteins (Proteins, Gene)
|3.||Caspase 3 (Caspase-3)
|4.||DNA (Deoxyribonucleic Acid)
|6.||N- (oxo- 5,6- dihydrophenanthridin- 2- yl)- N,N- dimethylacetamide hydrochloride
|8.||Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
|9.||Peroxynitrous Acid (Peroxynitrite)
|10.||2- ((R)- 2- methylpyrrolidin- 2- yl)- 1H- benzimidazole- 4- carboxamide
|1.||Drug Therapy (Chemotherapy)
|3.||Heterologous Transplantation (Xenotransplantation)